Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tuhura Biosciences Inc (HURA)

Tuhura Biosciences Inc (HURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,330
  • Shares Outstanding, K 60,721
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,680 K
  • EBIT $ -29 M
  • EBITDA $ -27 M
  • 60-Month Beta 0.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 3
  • High Estimate -0.12
  • Low Estimate -0.16
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4100 +204.88%
on 02/03/26
1.5100 -17.22%
on 02/11/26
+0.5347 (+74.75%)
since 01/12/26
3-Month
0.4100 +204.88%
on 02/03/26
2.2795 -45.16%
on 11/13/25
-0.9800 (-43.95%)
since 11/12/25
52-Week
0.4100 +204.88%
on 02/03/26
4.7700 -73.79%
on 02/13/25
-3.3000 (-72.53%)
since 02/12/25

Most Recent Stories

More News
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

TAMPA, Fla. , Feb. 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance...

HURA : 1.2300 (-4.65%)
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

TAMPA, Fla. , Feb. 2, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance...

HURA : 1.2300 (-4.65%)
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) Holders

HURA : 1.2300 (-4.65%)
TuHURA Biosciences Provides Corporate Update Following Recent Financing

Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda ® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special...

HURA : 1.2300 (-4.65%)
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

TAMPA, Fla. , Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance...

HURA : 1.2300 (-4.65%)
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities of...

HURA : 1.2300 (-4.65%)
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda ® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway,...

HURA : 1.2300 (-4.65%)
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression...

HURA : 1.2300 (-4.65%)
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

TAMPA, Fla. , Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.  (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance...

HURA : 1.2300 (-4.65%)
TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory NPM1-mutated Acute Myeloid...

HURA : 1.2300 (-4.65%)

Business Summary

TuHURA Biosciences Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA...

See More

Key Turning Points

3rd Resistance Point 1.9633
2nd Resistance Point 1.7367
1st Resistance Point 1.5133
Last Price 1.2300
1st Support Level 1.0633
2nd Support Level 0.8367
3rd Support Level 0.6133

See More

52-Week High 4.7700
Fibonacci 61.8% 3.1045
Fibonacci 50% 2.5900
Fibonacci 38.2% 2.0755
Last Price 1.2300
52-Week Low 0.4100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar